An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor

Published:2023-10 Issue:10 Volume:9 Page:e20465
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Tu Zegui^ORCID,Yu Yang,Tian Tian,Li Caili,Luo Jieyan

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference37 articles.

1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N. Engl. J. Med.,2018

2. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study;Garon;J. Clin. Oncol. : Offl. J. Am. Soc. Clin. Oncol.,2019

3. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N. Engl. J. Med.,2020

4. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab;Topalian;JAMA Oncol.,2019

5. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer;Gadgeel;J. Clin. Oncol. : Offl. J. Am. Soc. Clin. Oncol.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP